中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

自体骨髓干细胞治疗失代偿期肝硬化的临床观察

侯长利 尚建中 赵林华 王志鹏 李晓飞 刘小壮 张素娥 范燕峰

引用本文:
Citation:

自体骨髓干细胞治疗失代偿期肝硬化的临床观察

详细信息
  • 中图分类号: R575.2

The clinical research on autonomous bone marrow stem cells to treat decompensated cirrhosis

  • 摘要: 目的观察经肝动脉行自体骨髓干细胞治疗失代偿肝硬化患者的临床疗效及安全性。方法将我科2009年11月~2011年2月的住院乙型肝炎肝硬化失代偿患者50例配对分为2组。治疗组25例,对照组25例。治疗组,抽取自体骨髓200 ml,体外分离纯化骨髓干细胞制成10 ml细胞悬液,经肝动脉注入肝脏,分别在治疗后第4、8、16周观察实验室指标、临床症状体征及不良反应,并与对照组进行比较。结果治疗组治疗后所有患者症状均有不同程度改善,治疗后8周内腹水减轻16例(80%),食欲改善18例(90%),乏力好转19例(95%),腹胀减轻18例(90%)。对照组8周腹水减轻10例(50%),食欲改善12例(60%),乏力好转10例(50%),腹胀减轻8例(40%)。治疗组患者在干细胞治疗后第4周实验室指标开始出现变化,至第8周多项指标出现显著变化,治疗8周和16周时ALT、TBil、白蛋白(Alb)、总胆固醇(CHO)、凝血酶原时间(PT)与治疗前相比差异有统计学意义。治疗组与对照组在8周和16周时,ALT、TBil、PT、CHO各项指标相比,差异均有统计学意义。治疗前后CTP评分及MELD评分变化,从第4...

     

  • [1]Peng L, Xie DY, Lin BL, et al.Autologous bone marrowmesenchymal stem cell transplantation in liver failure patientscaused by hepatitis B:Short-term and long-term out-comes[J].Hepatology, 2011, 54:820-828.
    [2]Terai S, Sakaida I.Autologous bone marrow cell infusiontherapy for liver cirrhosis patients[J].Gastroenterol Hepa-tol, 2011, 18 (1) :23-25.
    [3]Dalakas E, Newsome PN, Boyle S, et al.Bone marrowstem cells contribute to alcohol liver fibrosis in humans[J].Stem Cells, 2010, 19 (9) :1417-1425.
    [4]Smets F, Najimi M.Sokal EM.Cell transplantation in thetreatment of liver diseases[J].Pediatr Transplant, 2008, 12 (1) :6-13.
    [5]Kharaziha P, Hellstrom PM, Noorinayer B, et al.Improvementof liver function in liver cirrhosis patients after autologous mes-enchymal stem cell injection:a phase I-II clinical trial[J].Gas-troenterol Hepatol, 2009, 21 (10) :1199-1205.
    [6]Lyra AC, Soares MB, da Silva LF, et al.Infusion of autologousbone marrow mononuclear cells through hepatic artery results ina short-term improvement of liver function in patients withchronic liver disease:a pilot randomized controlled study.Eur[J].Gastroenterol Hepatol, 2010, 22 (1) :33-42.
    [7]Ismail A, Fouad O, Abdelnasser A, et al.Stem cell therapyimproves the outcome of liver resection in cirrhotics[J].JGastrointest Cancer, 2010, 41 (1) :17-23.
    [8]王娟, 邵昕春, 郭庆, 等.自体骨髓干细胞治疗治疗失代偿期肝硬化[J].中国组织工程研究与临床康复, 2007, 11 (46) :9395-9397.
    [9]何金秋, 潘兴南, 王崇国, 等.自体骨髓间充质干细胞治疗治疗终末期肝病39例[J].中国组织工程研究与临床康复, 2010, 14 (45) :8521-8525.
    [10]Jiang YH, Jahagirdar BN, Reinhardt RL, et al.Pluripotencyof mesenchymal stem cells derived from adult marrow[J].Nature, 2002, 418 (6893) :41-49.
    [11]中华医学会.慢性乙型肝炎防治指南[J].中华传染病杂志, 2005, 23 (6) :421-431.
    [12]Bajek A, Olkowska, Drewa T.Mesenchymal stem cells as atherapeutic tool in tissue and organ regeneration[J].Postepy Hig Med Dosw (Online) , 2011, 24 (65) :24-32.
    [13]Amer ME, El-Sayed SZ, El-Kheir WA, et al.Clinical andlaboratory evaluation of patients with end-stage liver cellfailure injected with bone marrow-derived hepatocyte-likecells[J].Gastroenterol Hepatol, 2011, 23 (10) :936-941.
    [14]Gilchrist ES, Plevris JN.Bone marrow-derived stem cells inliver repair:10 years down the line[J].Liver Transpl, 2010, 16 (2) :118-129.
    [15]Moore KA, Lemischka IR.Stem cells and their niches[J].Science, 2006, 311 (5769) :1880-1885.
    [16]Le Blanc K, Pittenger M.Mesenchymal stem cells:progresstoward promise[J].Cytotherapy, 2005, 7 (1) :36-45.
    [17]Parekkadan B, van Poll D, Megeed Z, et al.Immunomodulationof activated hepatic stellate cells by mesenchymal stem cells[J].Biochem Biophys Res Commun, 2007, 363 (2) :247-252.
    [18]Greenbaum LE, Wells RG.The role of stem cells in liver repairand fibrosis[J].Biochem Cell Biol, 2011, 43 (2) :222-229.
  • 加载中
计量
  • 文章访问数:  2922
  • HTML全文浏览量:  12
  • PDF下载量:  649
  • 被引次数: 0
出版历程
  • 出版日期:  2012-05-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回